Lantheus Holdings, Inc LNTH

Lantheus Holdings, Inc. es un proveedor integrado de diagnósticos por imagen, terapéuticas dirigidas y soluciones de inteligencia artificial para encontrar, combatir y seguir condiciones médicas graves. La compañía clasifica sus productos comerciales en tres categorías: diagnósticos de precisión, oncología radioterapéutica y asociaciones estratégicas y otros ingresos. Sus productos en la categoría de diagnósticos de precisión incluyen DEFINITY, TechneLite, NEUROLITE, Xenon-133, Cardiolite, Galio-67 y Talio-201. Sus productos en la categoría de oncología radioterapéutica incluyen PYLARIFY y AZEDRA. Sus productos en la categoría de asociaciones estratégicas y otros ingresos incluyen RELISTOR, Índice Automatizado de Exploración Ósea (aBSI) y PYLARIFY AI. Además de sus productos comerciales y asociaciones estratégicas con terceros, también tiene programas de desarrollo clínico en curso, como 1095 y LMI 1195. Sus productos se venden tanto en los Estados Unidos como a nivel internacional.

• GlobeNewswire Inc. 30 sept

  Halper Sadeh LLC is Investigating Whether ITGR, FHB, INDV, LNTH are Obtaining Fair Deals for their Shareholders

  Halper Sadeh LLC, an investor rights law firm, is investigating four companies for potential securities law violations and breaches of fiduciary duties related to their proposed transactions. The firm is examining whether shareholders are receiving fair consideration and whether insider benefits may be prioritized over ordinary shareholder interests.

  

• GlobeNewswire Inc. 14 sept

  Curium™ announces FDA approval of BEXLUTRY lutetium Lu 177 dotatate injection for adults with SSTR-positive GEP-NETs

  Curium announced FDA approval of BEXLUTRY, a radioligand therapy for treating somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs) in adults. The approval marks Curium's first radioligand therapy and represents expansion into oncology therapeutics. The company also announced acquisitions of Abscint SA and a definitive merger agreement with Lantheus to create a global radiopharmaceutical leader.

  

• GlobeNewswire Inc. 7 sept

  Radioligand Therapy Market to Grow from USD 2.98 Billion in 2025 to USD 15.85 Billion by 2035, at a CAGR of 18.2% - SNS Insider

  The radioligand therapy market is projected to grow at an 18.2% CAGR through 2035, driven by increased prostate cancer and neuroendocrine tumor cases, FDA approvals for PSMA-targeted therapies like Pluvicto, and expanded isotope production capacity. North America dominates with 80.5% market share, while Asia-Pacific is the fastest-growing region at 21.5% CAGR.

  

• GlobeNewswire Inc. 4 ago

  Halper Sadeh LLC is Investigating Whether MKTX, SMTI, LNTH are Obtaining Fair Deals for their Shareholders

  Halper Sadeh LLC, an investor rights law firm, is investigating three companies for potential securities law violations and breaches of fiduciary duties related to their proposed acquisitions. The firm is examining whether shareholders are receiving fair consideration and whether insider benefits may be limiting superior competing offers.

  

• GlobeNewswire Inc. 3 ago

  Curium Announces Definitive Agreement to Merge with Lantheus

  Curium US has agreed to acquire Lantheus Holdings for $102.50 per share in cash at closing, plus up to $12.00 per share in contingent value rights, valuing the transaction at up to $8.0 billion. The combination aims to create a comprehensive radiopharmaceutical company spanning diagnostics and therapeutics across more than 70 countries, with the deal expected to close in the first half of 2027.